Related Experiment Video

Updated: Jun 24, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

Sigal Gery1, Qi Cao, Saskia Gueller

  • 1Davis Bldg. 5066, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. gerys@cshs.org

Journal of Leukocyte Biology
|March 19, 2009
PubMed

Insights

The adaptor protein Lnk inhibits the JAK2V617F mutation common in myeloproliferative disorders (MPD). Lnk acts as a negative regulator, offering insights into MPD molecular pathogenesis.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The JAK2V617F mutation is prevalent in myeloproliferative disorders (MPD), driving cytokine-independent hematopoietic cell proliferation.
  • Lnk (SH2B3) is an adaptor protein that negatively regulates hematopoietic cytokine signaling.

Purpose of the Study:

  • To investigate the role of Lnk as a regulator of JAK2V617F activity.
  • To explore the therapeutic potential of targeting Lnk in MPD.

Main Methods:

  • Investigated Lnk's effect on JAK2V617F signaling and transformation in Ba/F3-erythropoietin receptor cells.
  • Utilized CFU assays with Lnk-deficient murine bone marrow cells.
  • Examined Lnk-JAK2 interactions and phosphorylation.
  • Assessed Lnk levels in hematopoietic progenitors from MPD patients.

Main Results:

  • Lnk potently inhibits JAK2V617F constitutive activity, down-regulating its signaling and transformation.
  • Lnk-deficient cells show increased sensitivity to JAK2V617F transformation.
  • Lnk interacts with JAK2 via its SH2 and PH domains and is phosphorylated by JAK2V617F.
  • Elevated Lnk levels are observed in MPD patient progenitors, with expression induced by JAK2 activation.

Conclusions:

  • Lnk acts as a crucial endogenous negative regulator of JAK2V617F.
  • These findings provide novel insights into the molecular mechanisms underlying MPD development.
  • Targeting Lnk may offer a therapeutic strategy for MPD.

More Related Videos

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...